共 207 条
[1]
Wolk MJ(2014)ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of
[2]
Bailey SR(2006)A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers Clin Pharmacokinet 45 1201-1212
[3]
Doherty JU(2007)Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function J Clin Pharmacol 47 825-833
[4]
Douglas PS(2007)Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial J Nucl Cardiol 14 645-658
[5]
Hendel RC(2012)Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching JACC Cardiovasc Imaging 5 1014-1021
[6]
Kramer CM(2014)Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction Eur Heart J Cardiovasc Imaging 15 933-940
[7]
Gordi T(2015)The prognostic value of regadenoson myocardial perfusion imaging J Nucl Cardiol 22 1214-1221
[8]
Frohna P(2015)Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging J Nucl Cardiol 22 600-607
[9]
Sun HL(2016)Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients J Nucl Cardiol 23 101-112
[10]
Wolff A(2017)The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease J Nucl Cardiol 24 112-118